Cipla gets USFDA approvals for two drugs
Cipla, one of India`s largest pharmaceutical companies has received approvals for two drugs namely Stavudine and Levetiracetam from the United States Food and Drug Administration (USFDA).
While Stavudine will be available in solution form in the strengths of 1 mg/ml, Levetiracetam could be tablet in the strengths of 250 mg, 500 mg 750 mg respectively.
Stavudine is used for use in combination with other antiretroviral agents for the treatment of HIV infection in adults and children. Levetiracetam tablets are indicated as adjunctive therapy in treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy.
April 01, 2009